In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to EACVI Silver Members, Fellows of the ESC and Young combined Members

Noncompaction cardiomyopathy and cardiac MR imaging in Ege University

Session Poster session 2

Speaker Onur Akhan

Event : EuroCMR 2019

  • Topic : imaging
  • Sub-topic : Imaging - Other
  • Session type : Poster Session

Authors : O Akhan (Izmir,TR), E Demir (Izmir,TR), S Bayraktaroglu (Izmir,TR), F Ozerkan Cakan (Izmir,TR), S Nalbantgil (Izmir,TR)

Authors:
O Akhan1 , E Demir1 , S Bayraktaroglu2 , F Ozerkan Cakan1 , S Nalbantgil1 , 1Ege University, Cardiology Department - Izmir - Turkey , 2Ege University, Radiology Department - Izmir - Turkey ,

Citation:
European Heart Journal - Cardiovascular Imaging ( 2019 ) 20 ( Supplement 2 ), ii376

Noncompaction cardiomyopathy (NCCM) is a myocardial disorder characterized by excessive and prominent trabeculations associated with deep recesses that communicate with the left ventricular (LV) cavity. The original definition of LVNC required the generation of echocardiography- and CMR-based quantitative indexes that measure ratios between noncompacted and compacted layers of the LV wall. CMR imaging is increasingly utilized as a confirmatory imaging modality for evaluating suspected NCCM. LVNC can be regarded as an isolated entity or as one of the traits that may recur in cardiac and noncardiac diseases.We aimed to evaluate LVNC patients who referred our hospital and had advanced CMR imaging to indicate characteristics of these patients, detailed features of CMR reports and different groups of LVNC.
METHODS:Our study is a retrospective case control study.We analyzed the CMR imagings between 2006 and 2018 years in our radiology department with the key word 'noncompaction'.Then we reached 64 reports which showed us related to noncompaction cardiomyopathy.We evaluated these reports in terms of diagnostic criteria, hypertrabeculated areas, EF values and different groups of LVNC and accompanying disease. After evaluation of these reports we searched for these patients morbidity, mortality and cardiac operations.We didn't evalute patients for drugs using and other endpoints because of insufficient data.
RESULTS:After evaluation of CMR reports of which people had advanced imaging for differantial diagnosis of LVNC. In our study population 38(59%) of 64 patients were men. Mean age was 41 in between ages 18 - 73. Hypertrabeculation was prominently seen in the LV lateral wall followed by apex and inferior wall. Ratio of thickness of NC and C miyocardial layers at the site of maximal WT was measured and averaged around 2,9 (2,2-4). 10 patients had suspicious diagnosis for NCCM, because 4 of them didn't meet the criteria and 6 of them had insuffient data. 58 patients had datas about left ventricular ejection values, mean value 35 (17-69). Considering accompanying disorders, we observed 5 patients had CAD, 2 patients had primary valve disorders, 1 patient had connective tissue disorder, 1 patient had distrophin gene mutation, 1 patient had norofibramatosis type 1, 3 patients had peripartum cardiomyopathy, 3 patients had congenital heart anomalies, 3 patients had biventricular NC and 1 patient had isolated right ventricular NC.
Regarding to morbidity, mortality and cardiac operations, 6 patients had CRT-D implantation, 5 patients had LVAD implantation and 3 patients had heart transplantation story. 4 of 64 patients were exitus.
CONCLUSIONS:Although NCCM was included in the 2006 WHO classification of primary cardiomyopathies, it remains subject to controversy because of a lack of consensus on its etiology, pathophysiology, diagnosis,and management. There is a requirement a consensus about diagnostic imaging modalities and accompanying conditions about NC.

The free consultation period for this content is over.

It is now only available year-round to EACVI Silver Members, Fellows of the ESC and Young combined Members

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are